Yüklüyor......
EGFR-L861Q突变对TKI类药物敏感性预测分析及病例报道
BACKGROUND AND OBJECTIVE: The significant efficacy of tyrosine kinase inhibitors (TKIs) has been approved for advanced non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations. No clear evidence exists that EGFR-L861Q is sensitive to TKIs, and the...
Kaydedildi:
| Yayımlandı: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
中国肺癌杂志编辑部
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000112/ https://ncbi.nlm.nih.gov/pubmed/26383985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2015.09.11 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|